On April 14, Nektar Therapeutics (NKTR) jointly announced with Bristol Myers Squibb (BMY) to drop the global clinical development program for key cancer drug bempegaldesleukin
Nektar Therapeutics (NKTR) is a leading biotherapeutics company engaged in the development of a vigorous R&D pipeline for investigational drugs related to oncological and immunological
Nektar Therapeutics (NKTR), a biopharmaceutical company, has surged 10.34% in aftermarket trading session. Consequently, NKTR stock is trading at $11.95 at the time of the writing. The
At Stocktstelegraph.com, we are committed to helping investors make smart and profitable decisions. Our goal is to make investing easier and more accessible to everyone. We strive to provide the best and most reliable market information, news and analysis to ensure that our readers can make informed decisions.